Study of Incidence of Carcinoma Prostate in Central India With Reference To Gleason’s grading
Abstract
Introduction: Prostate cancer is the most common non dermatologic cancer and the second most common cause of cancer related death in men. Although most prostate cancers are relatively slow growing and remain clinically unrecognized, their course is often unpredictable in terms of its speed of progression, perhaps because of the considerable heterogeneity of the histologic grade and a multitude of other factors that affect tumor growth.
Material and method: The present study was carried out in the Department of Pathology, L.N. Medical College, Bhopa, India. It was both a prospective and a retrospective study of 310 prostatic biopsies /TUR (Trans-urethral resection) prostate chips.
Result: Among 310 Prostate biopsies, 276 cases (89%) were of benign prostatic hyperplasia, 8 cases (2.5%) were of benign prostatic hyperplasia with prostatic intraepithelial neoplasia and 26 cases (8.38%) were of adenocarcinoma prostate.
Discussion: Higher incidence of adenocarcinoma prostate could be due to the fact that in the absence of proper screening programme in our country, majority of the tumours are diagnosed incidentally when patients present with obstructive symptoms.
Downloads
References
2. Jemal A Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun 2006 Cancer statistics, 2006.CA Cancer J Clin56; 106-130. [PubMed]
3. Hankey B F Feuer E J,Clegg L X 1999 Cancer surveillance series: interpreting trends in prostate cancer part1: evidence of the effects of screening in recent prostate cancer incidence mortality and survival rates.
4. Gittes RF.Carcinoma of the prostate.N Engl J Med 1991,324: 236-245. [PubMed]
5. Shimada H,Misugi K,Sasaki Y,lizuka A, NishihiraH.Carcinoma of the prostate in childhood and adolescence.Report of acase and review of the literature.Cancer 1980. [PubMed]
6. Babian RJ,Melttlin C kane R, Murphy GP, Lee F, Drago JR, ChesleyA.The relationship of prostatic specific antigen to digital rectal examination and transrectal ultrasonography.Finding of the American cancer society national prostate cancer Detection project.1992,69:1195-1200.
7. McNeal JE,Redwine EA Freina FS 1988 Zonal distribution of prostatic adenocarcinoma.
8. Mostofi FK, Price EBJ. Tumors of the Male Genital System. vol. 8. Washington, DC: Armed Forces Institute ofP athology; 1973. 10.
9. Tumors of the Male Genital System[Atlas of Tumor Pathology, 2nd Series, Vol.8] [F. K. Mostofi, Edward B. Price Jr.].
10. Humphrey PA. gleason Grading and prognostic factor in carcinoma of the prostate Modern Pathology (2004) 17, 292–306. [PubMed]
11. American Cancer Society, authors. Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society; 2007.
12. Newcomer LM, Stanford JL, Blumenstein BA, Brawer MK. Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974 to 1994. J Urol. 1997;158:1127–1130. [PubMed]
13. Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol. 1990;143:742–746. [PubMed]
14. Scher HI, Isaacs JT, Zelefsky MJ, Prostate cancer. In: Abeloff MD, Armitage JO, Lichter AS,editors. Clinical Oncology. 2nd ed. New York, NY: Churchill Livingstone; 2000. pp. 1823–1884.
15. Epidemiological aspects. In: Kirby RS, Christmas TJ, Brawer MK: Prostate Cancer. London, England: Mosby, 1996, pp 23-33.
16. Dalkin BL,Fredrick R: PSA level in men without clinical evidence of prostatic carcinoma.J U 1933,15]:1837-39.
17. AprikianAG,ZhangZF,Fair WR(1994) Prostate adenocarcinoma in men younger than 50 years Cancer,74,1768-77. [PubMed]
18. Reissiggi A : Prostate carcinoma screening in the country of Tyrol, Austria.Cancer2000.Vol.80,issue9 page 1818-1829. [PubMed]
19. Newcomer LM, Stanford JL, Blumenstein BA. Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974 to 1994. J Urol. 1997;158:1127–1130. [PubMed]
20. Etzioni R, Tsodikov A, Mariotto A. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control 2008; 19:175. [PubMed]
21. Heijnsdijk EA, Wever EM, Auvinen A. Quality-of-life effects of prostate-specific antigen screening N Engl J Med 2012; 367:595. [PubMed]
22. Carter HB, Landis PK, Metter EJ. Prostate-specific antigen testing of older men. J Natl Cancer Inst. 1999;91:1733–1737. [PubMed]
23. Lilieby W Torlakovic E :Prognostic significance of histologic grading in patints with prostatic carcinoma who are assessed by Gleason and WHO grading systems in needle biopsies obtained prior to radiotherapy.Cancer2001:92:311-319.
24. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293:2095–21. [PubMed]
25. Chin-Chen Pen,,Potter SR,Partin AW,Epstein JI:The prognostic significance of Tertiary Gleason pattern of higher grade in Radical Prostatectomy specimen.A proposal to modify the Gleason Grading system. Am J Surg pathol:2000:24:563-569.
OAI - Open Archives Initiative
